P68 RNA Helicase Mediates PDGF-Induced Epithelial Mesenchymal Transition by Displacing Axin from β-Catenin  by Yang, Liuqing et al.
P68RNAHelicaseMediatesPDGF-Induced
Epithelial Mesenchymal Transition
by Displacing Axin from b-Catenin
Liuqing Yang,1 Chunru Lin,1 and Zhi-Ren Liu1,*
1Department of Biology, Georgia State University, University Plaza, Atlanta, GA 30303, USA
*Contact: biozrl@langate.gsu.edu
DOI 10.1016/j.cell.2006.08.036SUMMARY
The nuclear p68 RNA helicase (referred to as
p68) is a prototypical member of the DEAD
box family of RNA helicases. The protein plays
a very important role in early organ develop-
ment. In the present study, we characterized
the tyrosine phosphorylation of p68 under
platelet-derived growth factor (PDGF) stimula-
tion. We demonstrated that tyrosine phosphor-
ylation of p68 at Y593 mediated PDGF-stimu-
lated epithelial-mesenchymal transition (EMT).
We showed that PDGF treatment led to phos-
phorylation of p68 at Y593 in the cell nucleus.
The Y593-phosphorylated p68 (referred to as
phosphor-p68) promotes b-catenin nuclear
translocation via a Wnt-independent pathway.
The phosphor-p68 facilitates b-catenin nuclear
translocation by blocking phosphorylation of
b-catenin by GSK-3b and displacing Axin from
b-catenin. The b-catenin nuclear translocation
and subsequent interaction with the LEF/TCF
was required for the EMT process. These data
demonstrated a novel mechanism of phosphor-
p68 in mediating the growth factor-induced
EMT and uncovered a new pathway to promote
b-catenin nuclear translocation.
INTRODUCTION
Epithelial-mesenchymal transition (EMT) is a process by
which epithelial cells undergo dramatic morphology
changes marked by loss of their polarity and cell-cell con-
tacts (Savagner, 2001). The molecular hallmarks for EMT
are downregulation of epithelial cell adherens molecules,
such as E-cadherin, a-catenin, and g-catenin, and upre-
gulation of molecules of mesenchymal components,
such as vimentin, fibronectin, and smooth muscle actin
(sm-actin) (Yang et al., 2004a). The EMT process is vital
for morphogenesis during embryonic development and
tissue remodeling (Kalluri and Neilson, 2003; Savagner,2001). During tumor progression, substantial evidences
suggest that EMT plays a critical role for tumor cells to
leave an organized epithelial layer and gain the property
of invasiveness. Such changes usually initiate cancer
metastasis (KangandMassague, 2004;Thiery andChopin,
1999).
A number of cell signaling pathways stimulate EMT,
such as epidermal growth factor (EGF), transforming
growth-factor-b (TGF-b), hepatocyte growth factor (HGF),
and platelet-derived growth factor (PDGF) (Grande et al.,
2002; Lu et al., 2001; Lu et al., 2003; Nawshad et al.,
2005; Pagan et al., 1999). Many of these growth factors
act through their cell-surface receptors, receptor tyrosine
kinases (RTKs) (Blume-Jensen and Hunter, 2001). These
RTKs activate a series of downstream targets. For in-
stance, the canonical Ras pathway (Boyer et al., 1997)
and Src family of protein tyrosine kinases (Calautti et al.,
1998) play critical role(s) in induction of EMT under
growth-factor stimulation. Nuclear import of b-catenin is
another important player in EMT (Brabletz et al., 2005).
b-catenin undergoes nuclear translocation under stimula-
tions of Wnt signal and several other growth factors. The
nuclear b-catenin facilitates the transcription activation
by complex with transcriptional factor LEF/TCF (Nelson
and Nusse, 2004). Although the detailed mechanism by
which the b-catenin nuclear translocation facilitates EMT
is not well understood, it is believed that regulation of
components in cell adhesion and migration by complex
with LEF/TCF is important (Kim et al., 2002).
Evidence suggests that c-Abl plays a role downstream
of multiple growth-factor stimulations (Pendergast,
2002). PDGF stimulation activates the membrane pool of
c-Abl mediated by Src family of kinases in fibroblast cells.
The c-Abl kinase is a proto-oncogene nonreceptor tyro-
sine kinase. The kinase localizes to the plasmamembrane,
the cytoplasm, and the cell nucleus (Zhu andWang, 2004).
The activated c-Abl kinase targets a variety of cellular pro-
teins, including c-jun (Barila et al., 2000), Mdm2 (Goldberg
et al., 2002), and Dok1 (Woodring et al., 2004). It was
shown that the nuclear pool of c-Abl played a role in re-
sponse to DNA damage (Kharbanda et al., 1997; Rich
et al., 2000). On the other hand, the activation of the cyto-
plasmic pool of c-Abl leads to changes in cell morphology
in fibroblast cells (Plattner et al., 1999).Cell 127, 139–155, October 6, 2006 ª2006 Elsevier Inc. 139
Figure 1. P68 Is Tyrosyl Phosphorylated
in HT-29 Cells upon PDGF Stimulation
(A) Tyrosine phosphorylation of p68 in eight
cancer cell lines (indicated). The protein was
immunoprecipitated (IP) from nuclear extracts
and followed by immunoblot (IB) with appropri-
ate antibody (indicated). The IB:p68-rgg and
IB:H2A were the loading controls.
(B and C) Tyrosine phosphorylation of p68 in
HT-29 cells upon treatment with PDGF-BB at
different time points (indicated) (B) or different
doses (indicated) (C). The protein was IPed
(IP:PAbp68) from nuclear extracts and IB (IB)
with appropriate antibody (indicated). The
IB:p68-rgg was the loading control.
(D and E) The interaction of p68 with c-Abl was
detected by coIPs of p68 using antibody
(PAbp68) (D) or by coIP of c-Abl using antibody
against c-Abl (c-Abl[k12]) (E) followed by IBs
with appropriate antibody (indicated). The IPs
were carried out with nuclear extracts made
from the HT-29 cells that were treated/un-
treated (+/) with PDGF. Inputs were IB the ex-
tracts without IP (positive controls). Immuno-
precipitation with mouse IgG was the
negative control.The nuclear p68 RNA helicase is a prototypical member
of the DEAD box family of RNA helicases (Lane and Hoef-
fler, 1980). As an early example of a cellular RNA helicase,
the ATPase, and the RNA unwinding activities of p68 were
documented (Hirling et al., 1989; Iggo and Lane, 1989).
P68 plays a very important role in cell proliferation and
early organ development (Stevenson et al., 1998). The
protein may potentially have a role in the tumorigenesis
process (Causevic et al., 2001; Wei and Hu, 2001). We
have previously reported that p68 is phosphorylated at
multiple amino acid residues, including serine/threonine
and tyrosine (Yang et al., 2005; Yang and Liu, 2004). In
the present study, we characterized the tyrosine phos-
phorylation of p68 stimulated by PDGF-BB treatments
and found that tyrosine phosphorylation of p68 at Y593
is necessary for PDGF-stimulated EMT. We discovered
that PDGF treatment activated the c-Abl kinase, which
subsequently phosphorylated p68 at Y593 in the nucleus.
The phosphor-p68 promoted cytoplasmic b-catenin nu-
clear translocation via a Wnt-independent pathway. The
phosphor-p68 interacted with nuclear b-catenin, which
subsequently stimulated EMT.
RESULTS
PDGF Activates c-Abl, which Subsequently
Phosphorylates P68 at Y593
Our previous experiments demonstrated that p68 was
phosphorylated at tyrosine residues in cancerous cell lines
and the protein phosphorylation could be induced by
PDGF treatment in noncancerous cells (Yang et al.,
2005; Yang and Liu, 2004), suggesting that p68 may be
a downstream effecter of PDGF signaling. To understand
the role of the phosphor-p68 in mediating the effects of140 Cell 127, 139–155, October 6, 2006 ª2006 Elsevier Inc.PDGF signaling, we sought to identify the protein kinase
that phosphorylated p68 and to determine the phosphor-
ylation site(s). To search for a suitable study cell system,
we probed the phosphorylation status of p68 in several
human cancer cell lines. Consistent with our previous ob-
servations, p68 was phosphorylated at tyrosine residue in
the cancer cells, with the exception of HT-29, an epithelial
colon cancer cell line (Figure 1A). We then probed whether
p68 could be phosphorylated in HT-29 cells upon PDGF
treatment. P68 became rapidly phosphorylated at tyrosine
residue(s) in a time- and dose-dependentmanner in HT-29
cells (Figures 1B and 1C). We also found that c-Abl kinase
was activated upon PDGF stimulation, as demonstrated
by phosphorylation of c-Abl at Y245, and the phosphory-
lation of c-Jun, an authentic substrate of c-Abl (Figure 2B).
Moreover, the timing of the c-Abl activation correlated
closely with p68 phosphorylation (Figure 2B, data not
shown, also see Figure 5B). Thus, we speculate that p68
is a cellular target of c-Abl.
To test the possibility, we examined whether p68 inter-
acted with c-Abl under PDGF treatment. It was evident
that c-Abl coimmunoprecipitated with both endogenous
and exogenously expressed p68. The interaction between
p68 and c-Abl was dependent upon PDGF-BB treatment
(Figures 1D, 1E, S1A, and S1B). We next investigated
whether c-Abl phosphorylated p68. First, a bacterially ex-
pressed his-tagged p68 was phosphorylated by a re-
combinant c-Abl. Under the same condition, two control
proteins were not phosphorylated. The phosphorylation
of the his-p68 by the recombinant c-Abl was inhibited by
STI571, an Abl-specific inhibitor (Figure 2A). Second, the
recombinant his-p68 was phosphorylated by a complex
that was pulled down from nuclear extracts made from
PDGF-treated cells by using an antibody against c-Abl
Figure 2. Phosphorylation of P68 by c-Abl
(A) In vitro phosphorylation of his-p68 by recombinant c-Abl were detected by the autoradiography (KA), immunobloting with p-Tyr-100 (IB), and Coo-
massie blue staining (CBB) of the SDS-PAGE of each in vitro kinase reaction. his-NS3 andGST-p75IDwere two negative control proteins for the phos-
phorylation. Piceatannol is a kinase inhibitor that does not target c-Abl.
(B) Phosphorylation of his-c-Jun or his-p68 by IP complex using antibody against c-Abl from nuclear extracts made fromHT-29 cells that were treated
with different doses of PDGF-BB (indicated). c-Abl and phosphorylated c-Abl in the IP complex (IP:8E9) was examined by IBs with appropriate
antibody (indicated). The his-c-Jun or his-p68 was precipitated by Ni-TED beads and immunobloted by appropriate antibodies (indicated) after
phosphorylation by the IP complex.
(C) The Y245 phosphorylation of Flag-c-Abl-Myc (WT, Y245/412F, and P242/249E) in HT-29 cells with and without (+/) PDGF-BB treatment. The
Flag-c-Abl-Myc was precipitated by anti-Myc antibody (IP:Myc) followed by IB using antibody c-Abl (Y245) (IB:c-Abl[Y245[). The IB:FLAG was the
loading control.
(D) Tyrosine phosphorylation of endogenous p68 in HT-29 cells with and without (+/) PDGF treatment in the presence of Flag-c-Abl-Myc (WT, Y245/
412F, or P242/249E) were detected by IP of p68 (IP:PAbp68) followed by IBs via antibody p-Tyr-100 (IB:p-Tyr-100). The IB:p68-rgg was the loading
controls. Expression levels of Flag-c-Abl-Myc were indicated by IBs via anti-Flag antibody (IB:FLAG).
(E) CoIPs of HA-p68 with FLAG-Abl (IP:FLAG), WT or Y245/412F, at different times after PDGF stimulation (indicated) were detected by IB using an-
tibody 12CA5 (IB:12CA5). The inputs were the IB of 5% extracts by appropriate antibodies (indicated) without IP. IB:H2A was a loading control. The
pHM6 and pFLAG were the transfection of vectors.
(F) Tyrosine phosphorylation of p68 in HT-29 cells with andwithout (+/) PDGF treatment was detected by IB using antibody p-Tyr-100 (IB:p-Tyr-100).
P68was immunoprecipitated by antibody PAbp68 (IP:PAbp68) from the nuclear extracts. The cells were treatedwith nontargeting siRNA (NT) or c-Abl
siRNA (c-Abl). Knockdown of c-Abl was indicated by IB using antibody 8E9 (IB:8E9). The IB by p68-rgg is a positive control for the p68 precipitation.
The IB:H2A was a loading control.(Figure 2B). These experiments suggested that p68 can be
phosphorylated by nuclear c-Abl. To further confirm the
phosphorylation of p68 by c-Abl, we examined tyrosine
phosphorylation of endogenously or exogenously ex-
pressed p68 in HT-29 cells, in which c-Abl wild-type
(WT) or mutants (inactive mutant Y245/412F, constitu-tively active mutant P242/249E) (Furstoss et al., 2002;
Nagar et al., 2003) were expressed. PDGF treatment acti-
vated c-Abl as indicated by phosphorylation at Y245 in
WT and P242/249E (Figure 2C). The endogenous p68
was phosphorylated under PDGF treatment. However,
when increased amounts of inactive mutant Y245/412FCell 127, 139–155, October 6, 2006 ª2006 Elsevier Inc. 141
were expressed in the cells, tyrosine phosphorylation of
p68 declined and almost disappeared (Figure 2D). The in-
active c-Abl mutant prevented p68 from phosphorylation
by persistent interaction with p68 as revealed by coimmu-
noprecipitation experiments (Figure 2E). Expression of
constitutively active mutant P242/249E led to tyrosine
phosphorylation of p68 independent of PDGF (Fig-
ure 2D). Moreover, we examined tyrosine phosphory-
lation of p68 in HT-29 cells, in which c-Abl was knocked
down (over 90%) by RNA interference (RNAi). Under these
conditions, tyrosine phosphorylation of p68 was not de-
tected (Figure 2F). These results suggested that p68 was
phosphorylated by c-Abl in HT-29 cells under stimulation
of PDGF.
We next employed MALDI mass spectroscopy (MS) to
identify the phosphorylation site(s). The cellular p68 was
immunopurified from nuclear extracts made from PDGF-
treated HT-29 cells. The purified p68 was cleaved by
CNBr. MS spectrum revealed an m/z 1599.58 Da peak
that corresponded to an 80 Da shift of the m/z 1519.60
Da cleavage fragment (Figures 3A and 3B). The m/z
1599.58 peak can be purified by a Pi3 PhosphoTyrosine
column. Further, this shift is sensitive to tyrosine phospha-
tase 1B (PTP) (Figure 3C), indicating that the shift is indeed
due to tyrosine phosphorylation. To further confirm the ty-
rosine phosphorylation, we created two mutants, Y593F
and Y567F. The bacterially expressed his-p68s (WT and
the mutants) were subjected to phosphorylation by the
c-Abl. Both WT and mutant Y567F could be phosphory-
lated. In contrast, the mutant Y593F could not be phos-
phorylated (Figure 3D).We further tested the phosphoryla-
tion of p68 in HT-29 cells. Under stimulation of PDGF, WT
p68, and mutant Y567F were phosphorylated (Fig-
ure S1C). The Y593F mutant could not be phosphorylated
by c-Abl. The protein still interacted with c-Abl as revealed
by coimunoprecipitation of c-Abl with Y593F (Figure S1C).
There are two tyrosine residues in the 1519.60 Da frag-
ment (Y593, Y595). To determine the phosphorylation res-
idue, we created two mutants, Y593F and Y595F. The
Y595F was tyrosyl phosphorylated in HT-29 cells under
PDGF stimulation, but the Y593F was not (Figure 3E), sug-
gesting that Y593 was the phosphorylation site.
Y593 Phosphorylation of P68 Promotes EMT
To elucidate the functions of the phosphor-p68, we first
examined themorphology changes of cultured cells under
stimulation of PDGF. The HT-29 cells maintain very strong
cell-cell adhesion under normal culture conditions. The
cells display a typical round cobble-stone shape. Treat-
ment of HT-29 cells with PDGF-BB led to loss of cell-cell
contacts and cell scattering. The cell shape also under-
went dramatic changes. The cells showedmore of a fibro-
blastic morphology (Figure 4A). This phenomenon is indic-
ative of EMT. We then examined the effects of p68
phosphorylation at Y593 on these morphology changes.
First, p68 was knocked down more than 90% by RNAi
(Figure 4B). Knockdown of p68 abolished the effects of
PDGF on cell morphology changes (Figure 4A). We then142 Cell 127, 139–155, October 6, 2006 ª2006 Elsevier Inc.expressed p68 or mutants in the p68 knockdown cells
(Figure 4B). Expression of WT p68 restored the effects of
PDGF on the cell morphology changes. However, expres-
sion of the Y593F mutant did not restore the effects
(Figure 4A). These results indicated that phosphorylation
of p68 at Y593 was required for PDGF-stimulated EMT.
To further verify the functional role of the Y593 phosphor-
ylation in EMT, we probed the changes of molecular
markers that typically reflect EMT. The epithelial markers,
E-cadherin, a-catenin, and g-catenin, decreased dramat-
ically upon PDGF treatment, while the level of mesenchy-
mal markers, fibronectin, sm-actin, and N-cadherin, in-
creased significantly. Knockdown of p68 abolished the
effects of PDGF on the cellular levels of thesemarkers. Ex-
pression of WT p68 after knockdown of p68 restored the
effects of PDGF, especially the cellular level of sm-actin,
which was several-fold higher than those in cells without
p68 knockdown. Expression of p68 mutant Y593F did
not restore the effects of PDGF (Figure 4C). Since p68 is
phosphorylated by c-Abl, we tested whether c-Abl is re-
quired for PDGF-induced EMT. The changes in both cell
morphology and molecular markers for EMT in c-Abl
knockdown cells indicated that c-Abl was required for
the PDGF-induced EMT (Figure 4D). Hence, changes in
both cell morphology and molecular markers indicated
that PDGF promoted EMT in HT-29 cells. The phosphory-
lation of p68 at Y593 by c-Abl is required for the PDGF-
induced EMT. A very similar phenomenon was also ob-
served with another epithelial colon cancer cell line,
HCT116 (data not shown). To determine whether our ob-
servation is a general phenomenon, we examined the ef-
fects of the p68 phosphorylation on EMT in the MDCK
cell system. Exogenously expressed p68 was tyrosine
phosphorylated in MDCK cells upon EGF or TGF-b treat-
ment (Figure S2A). Expression of p68 enhanced the
EGF- or TGF-b-stimulated EMT in MDCK cells (Fig-
ure S2B). Knockdown of p68 largely blocked TGF-b-stim-
ulated EMT as revealed by the changes in morphology
(Figure S2C) and molecular markers of EMT (Figure S2D).
To determine whether the p68 phosphorylation is suffi-
cient to promote EMT, we delivered in vitro phosphory-
lated (via c-Abl) his-p68 to HT-29 cells. Most of the his-
p68 delivered to HT-29 cells localized to the cell nucleus
(Figure S3A). Although, one should be cautious in inter-
preting the experimental results of direct delivery of a reg-
ulatory protein, it was clear that the in vitro phosphorylated
p68 promoted EMT as revealed by changes in morphol-
ogy and cellular level of the EMT markers (Figure 4E).
The Phosphor-P68 Interacts with Nuclear b-Catenin
and Promotes the Translocation of b-Catenin to Cell
Nucleus via a Wnt-Independent Pathway
To understand the mechanism by which the phosphor-
p68 promotes EMT, we attempted to probe cellular pro-
teins that might interact with the phosphor-p68. Among
a number of potential candidates, b-catenin stood out
due to the important role of nuclear b-catenin in mediating
both cell proliferation and cell morphology change
Figure 3. c-Abl Phosphorylates P68 at Y593 in PDGF-Stimulated HT-29 Cells
(A) P68CNBr cleavage peptides recovered fromMALDI spectrum.MW,Obs andCalcd are the observed or calculatedmolecular weight, respectively.
(B) MALDI mass spectroscopy of CNBr cleaved endogenous p68 with PDGF treatment (upper panel) or without PDGF treatment (bottom panel).
(C) MALDI of CNBr cleaved p68 purified from PDGF-treated cells. The peptide mixture was treated with and purified by Pi3 phosphotyrosine QE kit
(Output), PTP after Pi3 purification (PTP), PP2A after Pi3 purification (PP2A). Input shows an untreated peptide mixture.
(D) In vitro phosphorylation of his-p68, WT or Y567F/Y593F mutants, by recombinant c-Abl were detected by the autoradiography (KA), immunoblot-
ing with p-Tyr-100 (IB:p-Tyr-100), and Commassie blue staining (CBB) of the SDS-PAGE of each in vitro kinase reaction.
(E) Tyrosine phosphorylations of exogenously expressed HA-p68s (WT, Y593F, or Y595F mutant) in HT-29 cells with and without (+/) PDGF treat-
ment were detected by IB using antibody p-Tyr-100 (IB:p-Tyr-100). The HA-p68s were IP from nuclear extracts (IP:HA). The IB:p68-rgg was a loading
control.(Behrens, 2000; Moon et al., 2004). We first carried out in
vitro binding analyses with recombinant his-p68s (WT or
mutants) and nuclear extracts made from PDGF untreated
HT-29 cells. The his-p68s (WT or mutants) were prephos-
phorylated by c-Abl in vitro. Figure 5A demonstrated that
b-catenin coprecipitated with his-p68 WT and the mutant
Y567F, but not with the mutant Y593F. The unphosphory-lated his-p68 did not coprecipitate with b-catenin (Fig-
ure 5A). The interaction between p68 and b-catenin was
further confirmed by coimmunoprecipitation of exoge-
nously expressedHA-p68with b-catenin in the nuclear ex-
tracts made from PDGF-treated or -untreated HT-29 cells
(Figure S3B). Simultaneous examination of the phosphor-
ylation status of the HA-p68 in the coprecipitates revealedCell 127, 139–155, October 6, 2006 ª2006 Elsevier Inc. 143
Figure 4. The Y593 Phosphorylation of P68 Is Required for PDGF-Stimulated EMT
(A) The morphologies of HT-29 cells were revealed by phase-contrast microscopy. The cells were treated (18/0 hr) with PDGF-BB. P68 was knocked
down (p68/NT) and HA-p68s, WT or Y593F, were expressed.144 Cell 127, 139–155, October 6, 2006 ª2006 Elsevier Inc.
that p68 was tyrosyl phosphorylated (Figures 5A and
S3B). The data suggested that the phosphor-p68 inter-
acted with b-catenin.
P68 interacted with both c-Abl and b-catenin. We next
sought to investigate the relationship between these two
molecular interactions. The time courses of these two in-
teractions were closely monitored in HT-29 cells that co-
expressed FLAG-c-Abl-Myc and HA-p68-his (Figure 5B).
First, p68 interacted with c-Abl kinase immediately after
PDGF stimulation (within 5 min) and reached a maximum
at 30 min, while p68 phosphorylation occurred almost si-
multaneously with a slight lagging behind. Although the
phosphorylation of p68 remained constant over a 180
min time course, the association of p68 with c-Abl started
to decline after 60 min of PDGF treatments and was al-
most completely abolished at 180 min. On the other
hand, the coprecipitation of b-catenin with p68 was al-
most undetectable until 30 min after PDGF treatment.
The interaction between b-catenin and p68 did not show
any significant decrease over a 180 min time course.
The results indicated that p68 was initially phosphorylated
by c-Abl and subsequently interacted with b-catenin, con-
sistent with the observation that only phosphor-p68 inter-
acted with b-catenin.
Since the phosphor-p68 interacted with nuclear b-
catenin, we proceeded to investigate whether the phos-
phor-p68 promoted nuclear accumulation of b-catenin.
Immunostaining of b-catenin showed that the protein
translocated to the cell nucleus in HT-29 cells under
PDGF stimulation. This translocation was largely blocked
by p68 knockdown. Transient expression of WT p68 re-
stored the pattern of nuclear staining of b-catenin. How-
ever, the Y593F-expressing cells demonstrated an exclu-
sive staining of b-catenin in the cell membrane (Figure 5C).
The role of p68 Y593 phosphorylation in promoting b-cat-
enin nuclear translocation was further examined by mon-
itoring the b-catenin in nuclear extracts and cell lysate
(Figure 5D). In the HT-29 cells without PDGF treatment,
there was a very low level of b-catenin in the nucleus.
Treatment of cells with PDGF promoted the translocation
of b-catenin to the nucleus. The effects of PDGF on en-
hancing b-catenin nuclear translocation were abolished
by p68 knockdown. However, the effects were restoredby exogenous expression of WT p68. The enhancement
correlated with the total level of p68 tyrosine phosphoryla-
tion. However, the nuclear b-catenin level was slightly de-
creased after expression of mutant Y593F in the p68
knockdown cells. The observed changes in nuclear b-cat-
enin were not due to a change in b-catenin expression, be-
cause the b-catenin level in cell lysate remained almost
constant. Thus, our data suggested that phosphorylation
of p68 played a role in promoting b-catenin translocation
into the cell nucleus. This phenomenonwas also observed
in HCT-116 cells (data not shown).
b-catenin is a component of cell adherens junctions,
connecting E-cadherin to a-catenins and g-catenins. Re-
pression of E-cadherin and a- g-catenins may free the
membrane b-catenin and increase the cytoplasmic b-cat-
enin. We therefore questioned whether the b-catenin nu-
clear translocation is a direct or an indirect consequence
of disruption of adheren junctions due to repression of
E-cadherin. To test this possibility, we examined the
effects of the in vitro phosphorylated p68 on b-catenin
nuclear translocation in HT-29 cells in which E-cadherin
was knocked down (Figure 5E) or E-cadherin was exoge-
nously overexpressed (Figure 5F). Knockdown of E-cad-
herin alone promoted b-catenin nuclear translocation to
some degree. Delivery of the phosphor-p68 dramatically
enhanced the b-catenin nuclear translocation in the E-
cadherin knockdown cells. On the other hand, b-catenin
was translocated to the nucleus in HT-29 cells if the phos-
phor-p68 was delivered regardless of whether the E-cad-
herin was overexpressed. Thus, we concluded that b-cat-
enin nuclear translocation was not a direct or an indirect
consequence of repression of E-cadherin.
Wnt signaling leads to b-catenin nuclear translocation
by blocking the GSK-3b-mediated phosphorylation of b-
catenin (Karim et al., 2004). We therefore investigated
whether b-catenin nuclear translocation promoted by the
phosphor-p68 overlapped with the Wnt signaling path-
way. P68 was knocked down in HT-29 cells. The cells
were subsequently treated by Wnt-1. It was evident that
b-catenin was translocated to the cell nucleus under
Wnt-1 treatment regardless of whether p68 was knocked
down or not (Figure 6A). The results suggested that b-cat-
enin nuclear translocation promoted by Wnt-1 signaling(B) Expression and phosphorylation of HA-p68s (WT or Y593F) in HT-29 cells were examined by IP of HA-p68s from nuclear extracts (IP:HA) followed
by IBs via antibodies p68-rgg (IB:p68-rgg) and p-Tyr-100 (IB:p-Tyr-100). The cells were treated by nontarget siRNA (NT) or p68 RNAi (p68). The total
p68s were monitored by IB via p68-rgg without IP (IB:p68-rgg). The IB:H2A was an internal control.
(C) Expression of epithelial proteins, E-cadherin, a-catenin, and g-catenin, and mysenchymal proteins, fibronectin, N-cadherin, and sm-actin, were
examined by immunobloting in HT-29 cells with and without (+/) PDGF treatment and with and without (p68/NT) p68 knockdown. The HA-p68s (WT
or Y593F) were expressed. The letters at the bottom indicated the same treatments of cells corresponding to the letter marks in panel (A).
(D) Cellular levels of c-Abl, E-cadherin, and vimetin in the HT-29 cells in which c-Abl was knocked down (c-Abl/NT) were examined by IB using ap-
propriate antibody (indicated). The cells were treated or untreated (+/) with PDGF-BB. The left panel was examined by IB. IB:H2A was a loading
control. The morphologies of HT-29 cells treated correspondingly as described in the left panel were revealed by phase-contrast microscopy (right
panel). The letters at the bottom of the left panel indicated the same treatments of cells corresponding to the letter marks on the right panel.
(E) Cellular levels of epithelial marker, E-cadherin, and mysenchymal markers, vimentin and sm-actin, in HT-29 cells were examined by IB using ap-
propriate antibody (indicated). The in vitro phosphorylated his-p68s (WT or Y593F), or unphosphorylated his-p68WT (WT) were delivered into the cells
(upper panel). The morphologies of HT-29 cells treated correspondingly as described in upper panel were revealed by phase-contrast microscopy
(lower panel). * The indicated his-tagged recombinant protein was incubated with Abl kinase in vitro and subsequently purified by Ni-TED beads. The
letters at the bottom of the upper panel indicated the same treatments of cells corresponding to the letter marks on the bottom panel.Cell 127, 139–155, October 6, 2006 ª2006 Elsevier Inc. 145
Figure 5. The Y593 Phosphorylated P68 Interacts with b-Catenin in the Nucleus and Promotes b-Catenin Nuclear Translocation
(A) The his-p68s (WT or Y567F/Y593F) were incubated with nuclear extracts made from HT-29 cells. The his-p68s were pretreated or untreated (+/)
by c-Abl for phosphorylation prior to the incubation. The his-p68s were precipitated by Ni-TED beads. The interaction of b-catenin with his-p68 was
examined by IB of the precipitates (IB:8E4). The inputs were IB of b-catenin in the extracts without IP. The loading control was Commassie staining of
the precipitated his-p68s (CBB).
(B) Time course of effects of PDGF on tyrosine phosphorylation of HA-p68, the HA-p68:FLAG-c-Abl interaction, and the HA-p68:b-catenin interaction
in HT-29 cells expressing Flag-c-Abl-Myc and HA-p68-his. The interactions were detected by IP:HA followed by IBs with appropriate antibodies146 Cell 127, 139–155, October 6, 2006 ª2006 Elsevier Inc.
does not require p68 RNA helicase. Our data also demon-
strated that b-catenin nuclear translocation promoted by
phosphor-p68 does not require Wnt. Our results, there-
fore, suggested that b-catenin nuclear translocation pro-
moted by Wnt signaling is phosphor-p68 independent.
To elucidate the mechanism by which the phosphor-
p68 promotes b-catenin nuclear translocation, we tested
whether the interaction between the phosphor-p68 and
b-catenin is required. We employed antibodies against
different sequence motifs of b-catenin (Table S1) to block
the interaction between the phosphor-p68 and b-catenin
and then examine the b-catenin nuclear translocation.
The antibodies were delivered to HT-29 cells. The cells
were then treated with PDGF. The antibodies against N-
terminal (7D11) and region of aa 35–50 (7A7) of b-catenin
blocked the interaction. No effects of antibodies against
C-terminal or core armadillo repeats on the interaction
were observed. Interestingly, an antibody against the N-
terminal sequence (aa 27–37) of b-catenin did not block
the interaction (Figure 6B). The antibodies that blocked
the b-catenin:phosphor-68 interaction also blocked the
b-catenin nuclear translocation. The antibodies that did
not block the interaction did not block the b-catenin nu-
clear translocation (Figure 6B). This experiment suggested
that the phosphor-p68 may interact with b-catenin at the
N terminus (likely aa 35–50 region) and the interaction of
the phosphor-p68 with b-catenin is necessary for b-cate-
nin nuclear translocation. Since the phosphorylation sites
of b-catenin by GSK-3b are located at Ser33/Ser37/Thr41
(Liu et al., 2002), it is possible that the phosphor-p68 also
interacted with the same sites, thereby blocking the GSK-
3b phosphorylation. To test this conjecture, we delivered
the in vitro phosphor-p68 into HT-29 cells. We then exam-
ined the phosphorylation of b-catenin at Ser33/Ser37/
Thr41. b-catenin was not phosphorylated in the presence
of the phosphor-p68 (Figure 6C). Lack of the b-catenin
phosphorylation was not due to downregulation or inacti-
vation of GSK-3b as revealed by the fact that there were
no significant changes in the cellular level and activity of
GSK-3b (Figure 6C). The inhibition of GSK-3b-mediated
b-catenin phosphorylation by the phosphor-p68 was fur-
ther confirmed by in vitro kinase assays with recombinant
his-p68, GSK-3b, and b-catenin (Figure 6D).
The above results suggested a direct role of the phos-
phor-p68 in promoting b-catenin nuclear translocation.
P68 must localize to the cytoplasm to fulfill this role. Totest whether the phosphor-p68 localized to cytoplasm,
we made cytoplasmic extracts from the PDGF-treated
and -untreated HT-29 cells. Immunoblotting detected
p68 in the extracts made from PDGF-treated cells but
not in the extracts made from PDGF-untreated cells
(Figure 6E). The results suggest that p68 is localized to
the cytoplasm.
The Phosphor-P68 ‘‘Displaces’’ Axin from b-Catenin
Facilitating b-Catenin Nuclear Translocation
P68 RNA helicase is an ATP-dependent RNA helicase
(Huang and Liu, 2002). To test whether the ATPase/heli-
case activities of p68 are required for the function of the
protein in mediating the EMT, we generated two p68 mu-
tants RGLD (helicase core motif V)/ LGLD and HRIGR
(helicase core motif VI) / HLIGR (referred to as LGLD
and HLIGR, respectively). The mutations abolished
ATPase and RNA-unwinding activities (Lin et al., 2005).
b-catenin nuclear translocation was analyzed in the cells
in which the in vitro phosphorylated his-p68s (WT or mu-
tants) were delivered. Mutations that abolished ATPase/
helicase activities of p68 also inhibited b-catenin nuclear
translocation (Figure 5E).
Requirement of ATPase activity for b-catenin nuclear
translocation is intriguing. To understand why the ATPase
activity was required, we probed proteins that associated
with cytoplasmic b-catenin in HT-29 cells with and without
PDGF treatment. Two proteins (at 120 and50 kDa) as-
sociated with b-catenin in PDGF-untreated cells but not in
the PDGF-treated cells. A protein (at70 kDa) associated
with b-catenin in PDGF-treated cells but not in the PDGF-
untreated cells (Figure 6F). The three proteins were identi-
fied by MOLDI-TOF/TOF (Figure S4). The 120 kDa band
was Axin, the 70 kDa band was p68 RNA helicase, and
the 50 kDa band was GSK-3b. We further verified the
identity of the proteins by immunoblotting using anti-
bodies against Axin, p68, and GSK-3b (Figure 7A). Similar
experiments were also carried out with cytoplasmic ex-
tracts made from p68 knockdown HT-29 cells. Unlike in
the cells in which p68 was not knocked down, the Axin
and GSK-3b associated with the cytoplasmic b-catenin
(Figure 7B). These results indicated that Axin and GSK-
3b only associated with cytoplasmic b-catenin in the ab-
sence of the phosphor-p68. The results suggest that,
upon interaction with b-catenin, the phosphor-p68 dis-
placed Axin-GSK-3b from the cytoplasmic b-catenin(indicated). The top input panels were the IB with indicated antibodies without IP. The input of b-catenin was IB of b-catenin in 5% extracts without IP.
The bottom panel is the quantitation of average four times of the IB signals. Error bars represent standard deviation (n = 4).
(C) Immunofluorescence staining of b-catenin in HT-29 cells, in which p68 RNA helicase was knocked down and p68s (WT or Y593F mutant) were
overexpressed in p68 knockdown cells. The cells were treated/untreated (+/) with PDGF-BB. The red signal represents staining of b-catenin.
(D) Immunobloting of the b-catenin level in the nuclear or whole cell lysates of HT-29 cells after various PDGF treatment times (0–18 hr). P68 was
knocked down and HA-p68s (WT or Y593F) were expressed (as indicated). The left panel is the IBs with appropriate antibodies (indicated). The right
panel is the quantitation of the average of four IB signals. Error bars represent standard deviation (n = 4).
(E and F) Immunoblot analyses of E-cadherin (IB:E-cadherin) and his-p68 (IB:27E8) in whole cell extracts and b-catenin in nuclear extracts (IB:8E4).
The in vitro phosphorylated/unphosphorylated his-p68s (WT [p68(pY)/p68], or [HLIGR(pY), LGLD(pY)] mutants) or control b-Gal (indicated) was de-
livered to the cells. The cells were treated with non-target RNAi (NT) or RNAi target E-cadherin (E-cadherin) in panel (E), or E-cadherin (Lenti.E-cad) or
LacZ (Lenti.LacZ) was expressed in the cells using the lentiviral system in panel (F). IB:Lamin A/C and 10% of total cellular b-catenin (IB:8E4) were
controls.Cell 127, 139–155, October 6, 2006 ª2006 Elsevier Inc. 147
Figure 6. The Y593 Phosphorylated P68 Promotes b-Catenin Nuclear Translocation via Wnt-Independent Pathway
(A) Nuclear b-catenin was examined by IB of nuclear extracts made from p68 knockdown (p68/NT) HT-29 cells with and without (+/) Wnt-1 stim-
ulation (10 ng/ml in culture medium). The cellular level of p68 was shown by IB using antibody p68-rgg (IB:p68-rgg). The IB:LaminA/C was a loading
control. The input was IB of b-catenin in 10% of whole cell extracts.
(B) Nuclear b-catenin was examined by IB of nuclear extracts of HT-29 cells (panel 4 from top). The tyrosine phosphorylation of p68 (panel 2 from top)
and b-catenin:p68 interaction (panel 3) were monitored by IB of coIPs (IP:PAbp68) using appropriate antibodies (indicated). Monoclonal antibodies
(indicated) against b-catenin were delivered to HT-29 cells. The cells were treated or untreated (+/) with PDGF. Rabbit IgG was used as a negative
control. IB:LaminA/C was a loading control. The input was IB of b-catenin in 10% of whole cell extracts.
(C) Analyses of the his-p68, phosphor-b-catenin, and total b-catenin in whole cell extracts made from HT-29 cells by IB using indicated antibody. The
phosphorylated/unphosphorylated [p68(pY)/p68] his-p68 was delivered to the cells (upper panel). The lower panel is kinase assay by incubating re-
combinant his-tagged Tau with the IP GSK3b from the HT-29 cells treated as upper panel. The his-Tau was pulled down by Ni-TED beads and148 Cell 127, 139–155, October 6, 2006 ª2006 Elsevier Inc.
complex, therefore facilitating b-catenin nuclear translo-
cation. In thismodel, the ATPase activity of p68may be re-
quired for the Axin-GSK-3b displacement. We therefore
tested whether the Axin-GSK-3b dissociated from the cy-
toplasmic b-catenin by the in vitro phosphorylated re-
combinant his-p68. b-catenin was immunoprecipitated
from cytoplasmic extracts made from PDGF-untreated
HT-29 cells. Immunoblotting demonstrated that p68 was
not present in the precipitates. The in vitro phosphorylated
p68 was then added to the precipitates in the presence
and absence of ATP. It was evident that Axin was dissoci-
ated from the precipitates only when the in vitro phosphor-
ylated p68 was added in the presence of ATP (Figure 7C).
If the in vitro phosphorylated HLIGR was added to the
precipitates, Axinwas not dissociated even in the presence
of ATP (Figure 7C). However, when the phosphor-p68
or phosphorylated HLIGR was added in the absence of
ATP, GSK-3b was coprecipitated with the b-catenin (Fig-
ure 7C). Thus, our data clearly suggested the following:
(1) the phosphor-p68 binds b-catenin and blocks its phos-
phorylation by GSK-3b, and (2) the phosphor-p68 ‘‘dis-
placed’’ Axin from cytoplasmic b-catenin. To further con-
firm the role of the phosphor-p68 in ‘‘displacing’’ Axin, the
p68s (WT, Y593F, LGLD, and HLIGR) were overexpressed
in HT-29 cells using the lentiviral system. Coimmunopreci-
pitation demonstrated that the exogenously expressed
WT, HLIGR, and LGLD interacted with cytoplasmic b-cat-
enin in PDGF-treated cells. However, the Y593F mutant
did not (Figure 7D). In the Y593F-expressing cells, both
GSK-3b and Axin coimmunoprecipitated with the cyto-
plasmic b-catenin. However, in the HLIGR- or LGLD-
expressing cells, Axin coimmunoprecipitated with b-cate-
nin and GSK-3b did not (Figure 7E). To determine whether
displacing Axin facilitates b-catenin nuclear translocation,
we examined nuclear b-catenin in HT-29 cells, where Axin
was knocked down by RNAi. It was evident that knock-
down of Axin led to accumulation of b-catenin in the cell
nucleus (Figure 7F).
The b-Catenin Nuclear Translocation Is Required
for EMT
We now asked whether the b-catenin nuclear transloca-
tion played a role in EMT. We first delivered the phos-
phor-p68 and the antibodies against b-catenin, 8E4, and
7A7 into HT-29 cells. In the presence of the phosphor-
p68 and the antibody 8E4, the cells underwent EMT as
demonstrated by changes in morphology (Figure 8A)
and EMT markers (Figure 8B). However, the EMT wasblocked by the antibody 7A7 (Figures 8A and 8B), and b-
catenin was not translocated to the cell nucleus in the
presence of the antibody 7A7. The nuclear b-catenin acti-
vates a number of genes by complex with LEF/TCF (East-
man and Grosschedl, 1999). To test whether this pathway
is required for the EMT, the TCF-1 was knocked down.
The TCF-1 knockdown (over 70%) was effective as dem-
onstrated by blocking the Wnt-1-stimulated b-catenin nu-
clear translocation (Figure 8C). We then examined the ef-
fects of TCF-1 knockdown on EMT in the presence of the
in vitro phosphor-p68. First, the b-catenin nuclear translo-
cation was not affected by TCF knockdown (Figure 8E).
However, EMT was almost completely blocked as re-
vealed by the changes in morphology (Figure 8E) and
EMT markers (Figure 8D). Thus, we concluded that the
b-catenin nuclear translocation and subsequent complex
with LEF/TCF was required for EMT mediated by the
phosphor-p68.
DISCUSSION
Nuclear translocation of b-catenin is a central player in the
Wnt signaling pathway, which can trigger cell proliferation,
differentiation, and migration (Nelson and Nusse, 2004).
The phosphor-p68 promotes cytoplasmic b-catenin nu-
clear translocation via a Wnt-independent pathway. This
is a newly discovered pathway for b-catenin nuclear trans-
location. We propose a model to illustrate the role of the
phosphor-p68 in promoting EMT through facilitating b-
catenin nuclear translocation (Figure 8F). Binding of the
phosphor-p68 to b-catenin precludes the contacts of
GSK-3b with b-catenin, thus preventing b-catenin from
phosphorylation. However, blocking the contacts of b-
catenin with GSK-3b is not sufficient to promote b-catenin
nuclear translocation, as ATPase/helicase activity of the
phosphor-p68 was not required for dissociating GSK-3b,
but the activity is required for b-catenin nuclear transloca-
tion. Our experiments showed that the ATPase/helicase
activity of the phosphor-p68 is employed to ‘‘displace’’
Axin from cytoplasmic b-catenin. Axin is an important pro-
tein factor that negatively regulates b-catenin nuclear
translocation. It was shown that Axin functioned to anchor
b-catenin in the cytoplasm (Tolwinski and Wieschaus,
2004). Thus, it is clear that the phosphor-p68 facilitates
b-catenin nuclear translocation by both blocking GSK-
3b phosphorylation and displacing the negative regulator
Axin.subjected to autoradiography (KA) or Coommasie blue staining (CBB). The top on the lower panel was the expression of GSK-3b examined by IB from
the whole cell extracts.
(D) In vitro phosphorylations of b-catenin by recombinant GSK-3b in the presence of phosphorylated/unphosphorylated his-p68s or his-c-Jun were
determined by the autoradiography (KA), immunoblotting with phosphor-b-catenin antibody (IB), and Coommasie blue staining (CBB) of the SDS-
PAGE of each in vitro kinase reaction.
(E) IB analyses of p68 in cytoplasmic (cyto.) or nuclear (Nuc.) extracts made from PDGF treated/untreated (+/) HT-29 cells. IB:Lamin A/C and IB:6C5
are the controls for nuclear or cytoplasmic proteins respectively.
(F) Silver staining the SDS-PAGE of coIP of cytoplasmic b-catenin. The b-catenin was precipitated from cytoplasmic extracts made from PGDF-
treated or -untreated (+/) HT-29 cells. Mouse IgG was used as a control pull down. The proteins that coprecipitated with b-catenin (identified by
MALDI-TOF/TOF) were indicated on the right side.Cell 127, 139–155, October 6, 2006 ª2006 Elsevier Inc. 149
Figure 7. Phosphor-P68 Displaces Axin1 from Cytoplasmic b-Catenin
(A and B) CoIP of GSK-3b, Axin1, and Pin1 with b-catenin in cytoplasmic extracts made from PDGF-treated or -untreated (+/) HT-29 cells were
detected by IBs using appropriate antibodies (indicated). The cytoplasmic b-catenin was IPed by antibody 10H8. In panel (A), IPs by mouse IgG
(IgG) was control IP. Inputs were the IBs without IP. In panel (B), the cells were treated by p68 siRNAs (p68) or nontarget siRNA (NT).
(C) Associations (beads) and dissociation (Superna) of Axin1 and GSK-3bwith the b-catenin that was immunoprecipitated from cytoplasmic extracts
made from PDGF-untreated HT-29 cells were detected by IBs using antibodies against Axin1 or GSK-3b (indicated). The coIP complexes were in-
cubated with the in vitro phosphorylated (pY) or unphosphorylated his-p68s (WT or HLIGR mutant) and in the presence or absence of ATP (+/).
IB:8E4 and IB:p68-rgg were loading controls.
(D) CoIPs of cytoplasmic b-catenin with HA-p68s (WT or mutants) were detected by IBs using antibody 8E4 (IB:8E4). The HA-p68s was IPed from
cytoplasmic extracts of PDGF-treated or -untreated (+/) HT-29 cells using anti-HA antibody (IP:HA). Inputs were the IBs of 5% extracts without IP.
(E) CoIPs of Axin1, GSK-3b, and Pin1 with cytoplasmic b-catenin were detected by IBs using appropriate antibodies (indicated). The b-catenin was
IPed from cytoplasmic extracts of PDGF-treated or -untreated (+/) HT-29 cells using antibody 10H8 (IP:10H8). HA-p68s (WT or mutants) was ex-
ogenously expressed in the cells (indicated). IB:8E4 was a control.
(F) Nuclear b-catenin (IB:8E4) was examined by IB of nuclear extracts made from HT-29 cells, in which Axin1 was siRNA knocked down (NT/Axin)
(IB:Axin). The IB:6C5 and IB:Lamin A/C and input b-catenin were loading controls.Since Axin is a scaffold protein that holds b-catenin and
GSK-3b in a b-catenin degradation complex, it is some-
what surprising that the p68 mutants that lack ATPase ac-
tivity dissociate GSK-3b without dissociation of Axin. The
best explanation is that phosphor-p68 and mutants phys-150 Cell 127, 139–155, October 6, 2006 ª2006 Elsevier Inc.ically contact Axin (the displacing target of p68). The con-
tact site is very close to the Axin:GSK-3b binding site. It is
conceivable that, although the phosphor-p68 mutants
(HLIGR and LGLD) cannot displace Axin, the mutants
physically contact Axin. This contact competes with the
Axin:GSK-3b interaction. Similar competition is observed
between the synaptic scaffolding molecule (S-SCAM)
and GSK-3b. Both molecules compete to bind to Axin in
neuro cells (Hirabayashi et al., 2004).
To promote cytoplasmic b-catenin nuclear transloca-
tion, the phosphor-p68 must be localized to the cyto-
plasm. The molecular mechanism underlining the translo-
cation of p68 is an open question in our proposed model
(Figure 8F). Our current hypothesis is that the tyrosine
phosphorylation may help p68 translocate to the cyto-
plasm. P68 was first observed predominantly localized
in the cell nucleus (Nicol et al., 2000). Recently, the protein
was shown to transiently localize to the cytoplasm (Ros-
sow and Janknecht, 2003). Our experiments also de-
tected the cytoplasmic p68. Interestingly, our data clearly
demonstrated that p68 translocated to the cytoplasm of
HT-29 cells upon PDGF stimulation (Figure 6E). Whether
this result suggests that only the phosphor-p68 localizes
to the cytoplasm requires further tests.
The requirement of ATPase/helicase activities of p68 in
b-catenin nuclear translocation brought about an interest-
ing question. What is the substrate(s) that stimulates
ATPase activity of the phosphor-p68? Our experiments
suggest the ‘‘displacing’’ role of the phosphor-p68 in dis-
sociating Axin from cytoplasmic b-catenin. This observa-
tion strongly suggests a novel protein-dependent ATPase
activity of p68 RNA helicase. Although, it was suggested
that the DExH/D box RNA helicases may function as
RNA unwindase to dissociate RNA-protein interactions
(Jankowsky et al., 2001). This is the first example of
a DExD/H box RNA helicase with the activity to dissociate
protein-protein interactions. An interesting question is
whether the Y593 phosphorylation of p68 is required for
the protein-dependent ‘‘displacing’’ activity. It is possible
that p68 RNA helicase may gain a ‘‘protein-dependent
ATPase’’ activity after the tyrosine phosphorylation. It is
also possible that the ‘‘protein-dependent ATPase’’ does
not depend upon phosphorylation. The activity is sub-
strate specific. Phosphorylation of p68 at Y593 facilitates
the recognition of the substrate b-catenin. In this regard, it
will be interesting to identify potential target protein(s) that
will stimulate the protein-dependent ATPase activity of
unphosphorylated p68.
The phosphorylation of p68 by c-Abl kinase is intriguing.
It was demonstrated that the plasmamembrane and cyto-
plasm pools of c-Abl kinase were activated by PDGF. It
was shown that Src kinase is activated upon the PDGF
treatment in fibroblast. The activated src will subsequently
phosphorylate and activate c-Abl of plasma membrane
and cytoplasm pools (Lu et al., 2001; Plattner et al.,
1999). Consistently, we previously observed that Src
was required for p68 tyrosine phosphorylation (Yang
et al., 2005). The question is, ‘‘Where is p68 phosphory-
lated by c-Abl?’’ Since p68 interacted with c-Abl in the
cell nucleus, and the recombinant p68 was phosphory-
lated by immunoprecipitated c-Abl from nuclear extracts,
our current hypothesis is that p68 is phosphorylated by
c-Abl in the nucleus. Our data indeed showed that nuclearc-Abl was activated in two epithelial cell lines upon PDGF
stimulation (Figure 2B and data not shown). On the con-
trary, Plattner and coworkers reported that the nuclear
c-Abl is not activated by PDGF in NIH-3T3 cells (Plattner
et al., 1999). One explanation for the contradictory obser-
vations is that the activated cytoplasmic pool of c-Abl
may migrate to the cell nucleus to phosphorylate p68. It
is also possible that the activation of nuclear c-Abl kinase
is cell- and tissue-type specific. Although c-Abl has been
implicated in a number of cellular processes, including dif-
ferentiation, stress responses, cell division, and cell adhe-
sions, our experiments suggest that c-Abl may also play
a role in mediating the effects of PDGF to promote EMT.
Another interesting phenomenon is that the Y593F mutant
does not seem to be a simple loss-of-function mutant. In
a number of overexpression experiments, the mutant
competed with the endogenous protein. We believe that
the mutant competes with the WT p68 for c-Abl binding
(Figure S1C). The consequence of binding to c-Abl by
the Y593F mutant is inhibition of the c-Abl activity, which
in turn blocks the phosphorylation of endogenous p68.
P68 RNA helicase is implicated in tissue and organ de-
velopmental processes, including early organ maturation
(Stevenson et al., 1998), embryogenesis (Seufert et al.,
2000), and wound healing (Kahlina et al., 2004). The find-
ings that phosphorylation(s) of p68 promoted the EMT
certainly provide a cellular and molecular basis for the de-
velopmental role(s) of the protein. More interestingly, we
observed a substantially higher level of tyrosine phosphor-
ylation(s) of p68 in metastatic cancer tissue samples than
those in primary sites. No tyrosine phosphorylation of p68
occurred in normal tissue samples (unpublished observa-
tions). Although we do not know whether the higher level
of tyrosine phosphorylation in metastatic cancer tissues
was due to phosphorylation at Y593, given that EMT is vi-
tal for an epithelial tumor to lose its polarity and progress
toward tumor invasion and metastasis (Kang and Mas-
sague, 2004; Yang et al., 2004a), and that the p68 Y593
phosphorylation promoted cell invasion, it is tempting to
speculate that the tyrosine phosphorylation at Y593 may
promote cancer metastasis.
EXPERIMENTAL PROCEDURES
Reagents and Antibodies
All recombinant growth factors, c-Abl kinase, GST-b-catenin, and his-
GSK3b, his-Jun, and Tau proteins were obtained from Upstate, Active
motif, PeproTech, and Biomol, respectively. The c-Abl inhibitor STI-
571 is a gift from Novartis. The antibodies used in this study are listed
in Table S1.
DNA Constructs, Recombinant Protein Expression, and
Purification
The HA-tagged p68 expression plasmid was constructed by subclon-
ing ORF of p68 from p68 expression vector (Huang and Liu, 2002) into
pHM6 vector (Roche). To construct Myc-tagged c-Abl expression vec-
tor, ORF of c-Abl was amplified from anmRNA pool of human HeLa S3
cells using primer, forward 50-AAGGAAAAAAGCGGCCGCGCAGCAGC
CTGGAAAAGTACT-30, reverse 50-CGGGATCCCCTCTGCACTATGTCA
CTGA-30. The cDNA of ORF was subcloned into pFLAG-myc-CMV -20Cell 127, 139–155, October 6, 2006 ª2006 Elsevier Inc. 151
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vector at Not I/BamH I sites (Sigma). Site-directed mutagenesis
was performed with mutation kits QuickChange site-directed muta-
genesis (Stratagene). The mouse E-cadherin cDNA was provided by
Dr. Gerhard Christofori at the Research Institute of Molecular Pathol-
ogy, Vienna, Austria and subcloned into the pLenti6/TOPO vector.
All cloned DNA and mutations were confirmed by DNA sequencing.
Recombinant 6Xhis-p68 and its derived mutants and other recombi-
nant proteins were expressed in bacterial BL21 and affinity purified
onNickel-TED beads by the same procedure described in our previous
report (Yang and Liu, 2004; Yang et al., 2004b).
Cell Culture and RNA Interference
A549, HeLa, HepG2, HT-29, HCT116, K562, SW620, T98G, WM115,
and MDCK cells were purchased from ATCC and grown by following
the vendor’s instructions. All DNAs or RNAs transfections were per-
formed using Lipofectamine 2000 by following the manufacturer’s in-
structions (Invitrogen). For the siRNA experiments, cells were grown
to 50% confluence and transfected with siRNA (200 pmole). The du-
plex RNA oligonucleotides for RNAi were purchased from Dharmacon.
siRNA olignucleotides against p68 (sense: GCAAGUAGCUGCUG
AAUAUUU; antisense: 50-PAUAUUCAGCAGCUACUUGCUU) were
purchased from Dharmacon Individual siGENOME Duplex. For tran-
sient expression of WT p68 or mutants in p68 knockdown cells, the
cells were transfected with the indicated plasmid DNA 24 hr after the
cells were transfected with siRNA and harvested after an additional
48 hr of incubation. For treatment of cells with PDGF-BB, the cells
were serum starved for 24 hr before the agents (20 ng/ml or doses in-
dicated in figures) were added to the cell-culture medium. After the
treatment of 30 min or the time indicated, the cells were immediately
harvested for nuclear extracts preparations.
Subcellular Extracts Preparation, Immunoprecipitation, and
Immunoblot Analyses
All nuclear extracts, cytoplasm, or cell lysate were made freshly after
appropriate treatments (indicated in figures) by using cell extracts
kits (Activemotif). The protein concentration of the extracts was deter-
mined using the Bradford assay (Bio-Rad). Immunoprecipitation ex-
periments and immunoblot analyses were performed as described in
previous studies (Liu et al., 1998). The blotting signals were detected
using SuperSignal West Dura Extended Duration Substrate (Pierce).
Quantitative analyses of immunoblot signals were obtained via densi-
tometry analyses using NIH Scion Image Software.
In Vitro Kinase Assay and Immune Complex Kinase Assay
The in vitro kinase assays were performed as described in previous
studies (Yang and Liu, 2004; Yang et al., 2004b).
For the immune complex kinase assay, endogenous c-Abl or exog-
enous FLAG-c-Abl proteins were immunoprecipitated from nuclear
extracts made from cells with or without PDGF treatments. The immu-
noprecipitates were washed twice in RIPA buffer, once in high-salt
buffer (100 mM Tris-HCl [pH 7.5], 500 mM NaCl) and once in kinase
buffer. Kinase reactions were performed for 30 min at 30C after
adding 1 mg appropriate substrates and 100 mM cold ATP and 5 mCi[32P]-g-ATP. Samples were separated by SDS-PAGE and analyzed
by autoradiography or immunoblotting with phosphotyrosine-specific
antibody.
Immunofluoresence and Imaging
The cells were seeded on chambered microslides (BD Biosciences)
and treated as indicated. The cells were washed, fixed, and permeabi-
lized with 4% formaldehyde and 0.1% Triton X-100 in 13 PBS. The
cells were then blocked with Image-iT FX signal enhancer (Molecular
Probes), and subsequently incubated with appropriate antibodies for
1 hr. After extensive wash, the samples were incubated with Alexa
Fluor 488 or 555 goat anti-mouse IgG (Molecular Probes) (1:1000) to
stain primary antibodies. Microslides were washed and mounted in
ProLong Gold antifade reagent with DAPI (Molecular Probes) and
viewed using a Zeiss LSM510 Confocal Microscope.
MALDI-Mass
The p68 was immunopurified from PDGF-treated or -untreated HT-29
cells and electrotransferred to nitrocellulose membranes. The p68
band was excised out from the membrane. The membrane was then
incubated with 100 mg/ml CNBr (Sigma) in 70% formic acid for 48 hr
at room temperature. After washes with 23500 ml of water and drying,
the resultant peptides mixture was then dissolved in 70 ml water and
analyzed by MALDI. To enrich phosphotyrosine-containing peptides,
the CNBr digestion mixtures were further purified by Pi3
PhosphoTyrosine-QE Kit (Nest Group Inc.). The purified peptide mix-
tures were further treated with PTP or PP2A. The mixtures were ana-
lyzed by mass spectroscopy.
Protein Delivery
The recombinant proteins or antibodies (indicated) were delivered into
HT-29 cells using the Chariot protein delivery kit (Active motif). Briefly,
1 mg of protein (in 100 ml PBS) was mixed with 6 ml of Chariot (in 100 ml
H2O). The mixture was incubated at room temperature to allow com-
plex to form. The cells were washed with serum-free medium. The
Chariot/protein complex was added to the cells with an additional
400 ml of serum-free medium. The cells were then incubated at 37C
for 2 hr to allow protein internalization.
Expression of P68s and E-Cadherin by Lentiviral System
Stable overexpression of HA-tagged p68 WT or Y593F, HLIGR, and
LGLD mutants were carried out using the ViralPower lentiviral expres-
sion system (Invitrogen) by following the manufacturer’s instructions.
The ORFs of p68 wild-type, Y593F, HLIGR, and LGLD mutants with
N-terminal HA-tag were cloned into pLenti6/TOPO (Invitrogen). The
mouse E-cadherin ORF was subcloned into the pLenti6/TOPO vector
fused with C-terminal V5 tag. The infections of HT-29 cells with the len-
tiviruses that carry p68s or E-cadherin were carried out in the presence
of 6 mg/mL of polybrene and 10 mM HEPES. Following transduction,
the HT-29 cells were selected by 8 mg/mL of Blasticidin (Invitrogen).Figure 8. b-Catenin Nuclear Translocation and TCF Were Required for EMT
(A and B) The morphologies of HT-29 cells (A) and IB (B) of cellular his-p68, E-cadherin, vimentin, and nuclear b-catenin using appropriate antibodies
(indicated). The antibodies (indicated) and in vitro phosphor-p68 were codelivered to the cells. Delivery of IgG + b-Gal was a negative control. IB:La-
minA/C was a loading control. The input was IB of b-catenin in 10% of whole cell extracts. The letters at bottom (B) indicated the same treatments of
cells corresponding to the letter marks in panel (A).
(C) IB of cellular TCF-1 and nuclear b-catenin in TCF-1 knockdown (TCF-1/NT) HT-29 cells with/without (+/) Wnt-1 stimulation. IB:LaminA/C was
a loading control. The input was IB of b-catenin in 10% of whole cell extracts.
(D and E) The morphologies of HT-29 cells (D) and IB (E) of cellular his-p68, TCF-1, E-cadherin, vimentin, and nuclear b-catenin using appropriate
antibodies (indicated). The cells were treated TCF-1 nontarget RNAi (NT) or RNAi target TCF-1 (TCF-1). The in vitro phosphor-p68 were delivered
to the cells. Delivery of b-Gal was a negative control. IB:LaminA/C was a loading control. The input was IB of b-catenin in 10% of whole cell extracts.
The letters at bottom (E) indicated the same treatments of cells corresponding to the letter marks in (D).
(F) A hypothetical model schematically illustration of the function of the phosphor-p68 in promoting EMT in response to PDGF stimulation.Cell 127, 139–155, October 6, 2006 ª2006 Elsevier Inc. 153
In Vitro Protein Complex Dissociation Assays
b-catenin was immunoprecipitated from cytoplasmic extracts made
from HT-29 cells using antibody 10H8. Immunoprecipitates were ex-
tensively washed with RIPA buffer (supplemented with protease inhib-
itor and phosphatase inhibitor cocktail) 8 times and subsequently incu-
bated with 250 ng indicated recombinant proteins in 50 ml ATPase
assay buffer containing 20 mM Tris-HCl, pH 7.5, 200 mM NaCl,
1 mM MgCl2, and 5 mM DTT with and without 4 mM ATP. The disso-
ciation reactions were incubated at 37C for 30 min. After incubation,
the beads and supernatants were separated by centrifugation and
subjected to immunoblotting analyses.
Supplemental Data
Supplemental Data include four figures and one table can be found
with this article online at http://www.cell.com/cgi/content/full/127/1/
139/DC1/.
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